D. Rachmilewitz

Publications348
h-index58
Citations25,055
Highly Influential Citations687
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • F. Karmeli
  • 143 Publications • 5,972 Citations
  • P. Rutgeerts
  • 1,677 Publications • 106,962 Citations
  • W. Sandborn
  • 2,038 Publications • 111,543 Citations
  • S. Hanauer
  • 984 Publications • 72,889 Citations
  • Publications
  • Influence
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
TLDR
Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks. Expand
Infliximab, azathioprine, or combination therapy for Crohn's disease.
TLDR
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy. Expand
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Expand
Infliximab maintenance therapy for fistulizing Crohn's disease.
TLDR
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks. Expand
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
TLDR
Mesalazine coated with Eudragit L is a safe, logical alternative to sulphasalazine in patients with active mild to moderate ulcerative colitis and remission rates were 74% and 81% in the two treatment groups respectively. Expand
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.
TLDR
The protective effects of Probiotics are mediated by their own DNA rather than by their metabolites or ability to colonize the colon, and live microorganisms are not required to attenuate experimental colitis because nonviable probiotics are equally effective. Expand
A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998
TLDR
The aim of this international Working Party was to develop a simple classification of Crohn's disease based on objective variables, and the allocation of patients to these 24 subgroups proved feasible and resulted in specific disease clusters. Expand
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
TLDR
The scheduled infliximab groups, particularly the 10 mg/kg group, had better CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ) responses than those in the episodic group. Expand
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.
TLDR
Results indicate that TLR9-triggered type I IFN has antiinflammatory functions in colitis and suggest that strategies to modulate innate immunity may be of therapeutic value for the treatment of intestinal inflammatory conditions. Expand
Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease.
TLDR
The decrease in NOx generation by cultured colonic mucosa induced by methylprednisolone suggests that NO synthase activity is induced during the culture and the steroid effect may contribute to its therapeutic effect. Expand
...
1
2
3
4
5
...